Platelet Function and Genotype after DES Implantation in East Asian Patients: Rationale and Characteristics of the PTRG-DES Consortiumopen access
- Her, Ae-Young; Jeong, Young-Hoon; Kim, Byeong-Keuk; Joo, Hyung Joon; Chang, Kiyuk; Park, Yongwhi; Song, Young Bin; Ahn, Sung Gyun; Suh, Jung-Won; Lee, Sang Yeup; Cho, Jung Rae; Kim, Hyo-Soo; Kim, Moo Hyun; Lim, Do-Sun; Shin, Eun-Seok
- Issue Date
- YONSEI UNIV COLL MEDICINE
- East Asia; platelet function; genotype; drug-eluting stent; coronary artery disease
- YONSEI MEDICAL JOURNAL, v.63, no.5, pp.413 - 421
- Journal Title
- YONSEI MEDICAL JOURNAL
- Start Page
- End Page
- Purpose: Platelet function test (PFT) results and genotype hold unique prognostic implications in East Asian patients. The aim of the PTRG-DES (Platelet function and genoType-Related long-term proGnosis in Drug-Eluting Stent-treated Patients with coronary artery disease) consortium is to assess the clinical impact thereof on long-term clinical outcomes in Korean patients with coronary artery disease during dual antiplatelet therapy (DAPT) including clopidogrel. Materials and Methods: Searching publications on the PubMed, we reviewed clopidogrel treatment studies with PFT and/or genotype data for potential inclusion in this study. Lead investigators were invited to share PFT/genotype results, patient characteristics, and clinical outcomes to evaluate relationships among them. Results: Nine registries from 32 academic centers participated in the PTRG-DES consortium, contributing individual patient data from 13160 patients who underwent DES implantation between July 2003 and August 2018. The PTRG-PFT cohort was composed of 11714 patients with available VerifyNow assay results. Platelet reactivity levels reached 218 +/- 79 P2Y12 reaction units (PRU), and high on-clopidogrel platelet reactivity based on a consensus-recommended cutoff (PRU >208) was observed in 55.9%. The PTRGGenotype cohort consisted of 8163 patients with candidate genotypes related with clopidogrel responsiveness. Of those with cytochrome P450 (CYP) 2C19 genotype, frequencies of carrying one and two loss-of-function allele (s) (*2 or *3) were 47.9% (intermediate metabolizers) and 14.2% (poor metabolizers), respectively. Conclusion: The PTRG-DES consortium highlights unique values for on-clopidogrel platelet reactivity and CYP2C19 phenotype that may be important to developing optimal antiplatelet regimens in East Asian patients. Trial Registration: ClinicalTrials.gov Identifier: NCT04734028.
- Files in This Item
- There are no files associated with this item.
- Appears in
- College of Medicine > Department of Medicine > Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.